{
    "2019-09-20": [
        [
            {
                "time": "2018-01-03",
                "original_text": "The Opioid Crisis Could Hurt Investors. Hereâ€™s How.",
                "features": {
                    "keywords": [
                        "opioid crisis",
                        "hurt investors"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Should Johnson & Johnson Investors Worry About Opioid Lawsuits?",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "opioid lawsuits",
                        "investors worry"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "How Opioid Lawsuits Could Hurt Investors",
                "features": {
                    "keywords": [
                        "opioid lawsuits",
                        "hurt investors"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Gilead, AbbVie Are Innovative, but May Be Underappreciated",
                "features": {
                    "keywords": [
                        "Gilead",
                        "AbbVie",
                        "innovative",
                        "underappreciated"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "The New Capitalism Is Looking a Lot Like the Old Capitalism",
                "features": {
                    "keywords": [
                        "new capitalism",
                        "old capitalism"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "economy"
                    ],
                    "causal_factor": "false",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "The Zacks Analyst Blog Highlights: Johnson & Johnson, Boeing, Broadcom, Anthem and Allstate",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Johnson & Johnson",
                        "Boeing",
                        "Broadcom",
                        "Anthem",
                        "Allstate"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "industrials",
                        "technology",
                        "insurance"
                    ],
                    "causal_factor": "false",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "Trovagene's Onvansertib Shows Response in Phase Ib AML Study",
                "features": {
                    "keywords": [
                        "Trovagene",
                        "Onvansertib",
                        "Phase Ib",
                        "AML Study"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-01-12",
                "original_text": "Walgreens Boots, Pfizer share gains contribute to Dow's nearly 75-point jump",
                "features": {
                    "keywords": [
                        "Walgreens Boots",
                        "Pfizer",
                        "share gains",
                        "Dow's jump"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "retail"
                    ],
                    "causal_factor": "false",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-15",
                "original_text": "Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates",
                "features": {
                    "keywords": [
                        "FDA",
                        "expanded use",
                        "MRK/J&J",
                        "drugs"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-01-16",
                "original_text": "Bull of the Day: Amgen (AMGN)",
                "features": {
                    "keywords": [
                        "Bull of the Day",
                        "Amgen"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}